XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.20.4

REVENUE (Tables) | 3 Months Ended
--- | ---
Jan. 31, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended January 31,
| 2021 |  | 2020
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 224 |  |  | $ | 179 |  |  | $ | 152 |  |  | $ | 555 |  |  | $ | 209 |  |  | $ | 167 |  |  | $ | 118 |  |  | $ | 494 |
Europe | 190 |  |  | 147 |  |  | 100 |  |  | 437 |  |  | 167 |  |  | 133 |  |  | 92 |  |  | 392 |
Asia Pacific | 308 |  |  | 206 |  |  | 42 |  |  | 556 |  |  | 262 |  |  | 170 |  |  | 39 |  |  | 471 |
Total | $ | 722 |  |  | $ | 532 |  |  | $ | 294 |  |  | $ | 1,548 |  |  | $ | 638 |  |  | $ | 470 |  |  | $ | 249 |  |  | $ | 1,357 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  |
| January 31, |  |
| 2021 |  | 2020 |  |  |  |
| (in millions) |  |  |  |
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 521 |  |  | $ | 423 |  |  |  |  |
Chemical and Energy | 328 |  |  | 312 |  |  |  |  |
Diagnostics and Clinical | 216 |  |  | 194 |  |  |  |  |
Food | 162 |  |  | 130 |  |  |  |  |
Academia and Government | 142 |  |  | 141 |  |  |  |  |
Environmental and Forensics | 179 |  |  | 157 |  |  |  |  |
Total | $ | 1,548 |  |  | $ | 1,357 |  |  |  |  |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 681 |  |  | $ | 593 |  |  |  |  |
Non-instrumentation and other | 867 |  |  | 764 |  |  |  |  |
Total | $ | 1,548 |  |  | $ | 1,357 |  |  |  |  |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2021:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2020 |  | $ | 446 |
Net revenue deferred in the period |  | 197 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (186) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 20 |
Currency translation and other adjustments |  | 8 |
Ending balance as of January 31, 2021 |  | $ | 485 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration